

Title (en)
MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Title (de)
MUSKARINISCHE KOMBINATIONEN UND DEREN VERWENDUNG ZUR BEKÄMPFUNG HYPOCHOLINERGISCHER STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS

Title (fr)
COMBINAISONS MUSCARINIQUES ET LEUR UTILISATION POUR LUTTER CONTRE DES TROUBLES HYPOCHOLINERGIQUES DU SYSTÈME NERVEUX CENTRAL

Publication
EP 3347012 A4 20190417 (EN)

Application
EP 16845102 A 20160909

Priority
• US 201562217081 P 20150911
• US 201662351382 P 20160617
• US 2016050907 W 20160909

Abstract (en)
[origin: WO2017044714A1] A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.

IPC 8 full level
A61K 31/216 (2006.01); **A61K 9/70** (2006.01); **A61K 31/166** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/439** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/454** (2006.01); **A61K 31/517** (2006.01); **A61K 45/06** (2006.01); **A61P 25/00** (2006.01); **A61P 25/14** (2006.01); **A61P 25/18** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 31/166 (2013.01); **A61K 31/216** (2013.01); **A61K 31/4178** (2013.01); **A61K 31/439** (2013.01); **A61K 31/4439** (2013.01); **A61K 31/454** (2013.01); **A61K 31/517** (2013.01); **A61K 45/06** (2013.01); **A61P 25/00** (2018.01); **A61P 25/14** (2018.01); **A61P 25/18** (2018.01); **A61P 25/24** (2018.01); **A61P 25/28** (2018.01); **A61P 43/00** (2018.01); **A61K 9/7023** (2013.01)

C-Set (source: EP)
1. **A61K 31/216 + A61K 2300/00**
2. **A61K 31/439 + A61K 2300/00**
3. **A61K 31/4178 + A61K 2300/00**
4. **A61K 31/4439 + A61K 2300/00**
5. **A61K 31/517 + A61K 2300/00**
6. **A61K 31/454 + A61K 2300/00**
7. **A61K 31/166 + A61K 2300/00**

Citation (search report)
• [E] WO 2016144719 A1 20160915 - CHASE THOMAS N [US]
• [E] WO 2016144749 A1 20160915 - CHASE THOMAS N [US], et al
• [E] WO 2017015349 A1 20170126 - CHASE PHARMACEUTICALS CORP [US]
• [E] WO 2017044693 A1 20170316 - CHASE PHARMACEUTICALS CORP [US]
• [E] WO 2017147104 A1 20170831 - CHASE PHARMACEUTICALS CORP [US]

Citation (examination)
• SRAMEK J J ET AL: "THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMER'S DISEASE", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 35, 1 January 1995 (1995-01-01), pages 800 - 806, XP000563129, ISSN: 0091-2700
• See also references of WO 2017044714A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2017044714 A1 20170316; CA 2996719 A1 20170316; EP 3347012 A1 20180718; EP 3347012 A4 20190417

DOCDB simple family (application)
US 2016050907 W 20160909; CA 2996719 A 20160909; EP 16845102 A 20160909